K2M Group (NASDAQ:KTWO) issued an update on its FY17 earnings guidance on Monday morning. The company provided EPS guidance of -0.86 to -0.81 for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.85). The company issued revenue guidance of $257.5-258.1 million, compared to the consensus revenue estimate of $255.93 million.

K2M Group (NASDAQ:KTWO) opened at $20.20 on Wednesday. K2M Group has a 12 month low of $16.44 and a 12 month high of $25.99. The firm has a market capitalization of $875.24, a P/E ratio of -21.04 and a beta of 1.34. The company has a quick ratio of 1.67, a current ratio of 3.06 and a debt-to-equity ratio of 0.29.

K2M Group (NASDAQ:KTWO) last announced its earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The business had revenue of $62.65 million during the quarter, compared to analysts’ expectations of $62.69 million. During the same quarter in the previous year, the firm earned ($0.19) EPS. K2M Group’s quarterly revenue was up 5.6% on a year-over-year basis. research analysts forecast that K2M Group will post -0.85 earnings per share for the current fiscal year.

KTWO has been the topic of a number of research analyst reports. Piper Jaffray Companies restated an overweight rating and issued a $28.00 target price on shares of K2M Group in a research note on Tuesday, October 10th. Oppenheimer set a $24.00 price target on shares of K2M Group and gave the stock a buy rating in a report on Wednesday, October 18th. Royal Bank of Canada reaffirmed a buy rating and issued a $26.00 price target on shares of K2M Group in a report on Friday, September 22nd. Zacks Investment Research raised shares of K2M Group from a hold rating to a buy rating and set a $25.00 price target on the stock in a report on Wednesday, October 4th. Finally, Wells Fargo & Co lowered their price target on shares of K2M Group from $28.00 to $23.00 and set an outperform rating on the stock in a report on Tuesday, October 10th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. K2M Group has a consensus rating of Buy and a consensus target price of $24.50.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/01/10/k2m-group-ktwo-issues-fy17-earnings-guidance.html.

About K2M Group

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.